Superior Long-Term Survival with Fludarabine-Melphalan RIC Regimen in Older AML/MDS Patients: A Propensity Score Analysis of CIBMTR Data

Key Points

• Survival rates significantly increase with the fludarabine-melphalan regimen over traditional treatments.
• Key evidence reveals a 25% improvement in long-term survival for older AML/MDS patients using this regimen.
• Propensity score analysis utilized data from the CIBMTR, ensuring robust comparisons across patient demographics.
• The findings support the need for tailored therapies in older populations facing leukemia and myelodysplastic syndromes.